HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Josef Rüschoff Selected Research

Biomarkers (Surrogate Marker)

1/2022Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.
1/2015MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.
4/2013Frequency of HER-2 positivity in rectal cancer and prognosis.
4/2009Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.
12/2008Proficiency testing of immunohistochemical biomarker assays in breast cancer.
1/2008Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
11/2006Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis.
1/2006Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
9/2005Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Josef Rüschoff Research Topics

Disease

36Neoplasms (Cancer)
01/2022 - 08/2003
20Breast Neoplasms (Breast Cancer)
01/2019 - 01/2004
13Colorectal Neoplasms (Colorectal Cancer)
11/2021 - 06/2002
9Stomach Neoplasms (Stomach Cancer)
01/2019 - 08/2002
8Rectal Neoplasms (Rectal Cancer)
10/2016 - 02/2012
7Adenoma (Adenomas)
04/2013 - 09/2003
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2021 - 11/2003
6Microsatellite Instability
11/2021 - 06/2002
6Carcinoma (Carcinomatosis)
11/2018 - 08/2002
4Adenocarcinoma
10/2016 - 06/2003
4Carcinogenesis
01/2008 - 08/2003
3Lung Neoplasms (Lung Cancer)
11/2018 - 02/2015
3Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer)
09/2006 - 05/2005
2Rhabdomyosarcoma
01/2022 - 01/2014
2Endometrial Neoplasms (Endometrial Cancer)
11/2021 - 07/2021
2Neoplasm Metastasis (Metastasis)
04/2013 - 01/2013
2Mucinous Adenocarcinoma (Mucinous Carcinoma)
11/2004 - 06/2003
2Colonic Neoplasms (Colon Cancer)
09/2003 - 08/2002
1Nervous System Neoplasms (Neoplasms, Nervous System)
01/2022
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2019
1Melanoma (Melanoma, Malignant)
11/2018
1Squamous Cell Carcinoma of Head and Neck
11/2018
1Necrosis
10/2016
1Esophageal Neoplasms (Esophageal Cancer)
03/2015
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2015
1Hemangiosarcoma (Angiosarcoma)
01/2015
1Clear Cell Sarcoma
01/2015
1Neurofibrosarcoma (MPNST)
01/2015
1Sarcoma (Soft Tissue Sarcoma)
01/2015
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/2015
1Leiomyosarcoma
01/2015
1Polyps
04/2013
1Chromosomal Instability (Chromosome Stability)
04/2013
1Metaplasia
10/2010
1Neutropenia
08/2010
1Nausea
08/2010
1Vomiting
08/2010

Drug/Important Bio-Agent (IBA)

19Proteins (Proteins, Gene)FDA Link
11/2021 - 03/2004
17Trastuzumab (Herceptin)FDA Link
01/2019 - 11/2003
11human ERBB2 proteinIBA
01/2022 - 01/2007
9Biomarkers (Surrogate Marker)IBA
01/2022 - 09/2005
6ErbB Receptors (EGF Receptor)IBA
01/2022 - 12/2008
6Monoclonal AntibodiesIBA
02/2015 - 06/2003
4B7-H1 AntigenIBA
12/2021 - 10/2016
4ParaffinIBA
01/2014 - 01/2003
3Immune Checkpoint InhibitorsIBA
11/2021 - 11/2018
3Messenger RNA (mRNA)IBA
08/2018 - 08/2002
3Indicators and Reagents (Reagents)IBA
01/2017 - 01/2004
3DNA (Deoxyribonucleic Acid)IBA
10/2016 - 06/2002
3RNA (Ribonucleic Acid)IBA
10/2016 - 08/2002
3Capecitabine (Xeloda)FDA Link
03/2015 - 05/2012
3Calcibiotic Root Canal SealerIBA
04/2013 - 07/2007
3Fluorouracil (Carac)FDA LinkGeneric
01/2013 - 04/2004
2dostarlimabIBA
11/2021 - 07/2021
2pembrolizumabIBA
11/2021 - 07/2021
2Lapatinib (GW572016)FDA Link
01/2019 - 03/2015
2AcetoneIBA
06/2015 - 02/2012
2Tyrosine Kinase InhibitorsIBA
03/2015 - 02/2015
2Formaldehyde (Formol)FDA Link
01/2014 - 01/2003
2Cetuximab (Erbitux)FDA Link
12/2013 - 09/2013
2Hormones (Hormone)IBA
04/2013 - 12/2008
2SilverIBA
04/2013 - 05/2012
2Nicotinamide N-MethyltransferaseIBA
11/2006 - 09/2005
2Tumor Biomarkers (Tumor Markers)IBA
11/2006 - 09/2005
2betaIG-H3 protein (keratoepithelin)IBA
09/2005 - 04/2005
2Codon (Codons)IBA
08/2005 - 04/2005
2Insulin-Like Growth Factor I (IGF-1)IBA
12/2004 - 08/2003
2Insulin-Like PeptidesIBA
12/2004 - 08/2003
2Insulin-Like Growth Factor II (Somatomedin A)IBA
12/2004 - 08/2003
1Programmed Cell Death 1 ReceptorIBA
12/2021
1Estrogen ReceptorsIBA
08/2021
1serum P-component (CIt)IBA
01/2019
1NivolumabIBA
11/2018
1Diagnostic Reagent KitsIBA
11/2018
1ErbB-2 ReceptorIBA
03/2018
1Phenobarbital (Luminal)FDA Link
08/2016
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2015
1Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2013
1theasinensin AIBA
04/2013
1AC133 AntigenIBA
01/2013
1Glycoproteins (Glycoprotein)IBA
01/2013
1Cisplatin (Platino)FDA LinkGeneric
05/2012
1Epidermal Growth Factor (EGF)IBA
10/2009
1SteroidsIBA
12/2008
1GelsIBA
11/2006
1polyacrylamideIBA
11/2006
1AnnexinsIBA
11/2006
1N-acetyltalosaminuronic acid (NAT)IBA
09/2006
1AcetyltransferasesIBA
09/2006
1Cyclin D1IBA
05/2006
1NucleosidesIBA
01/2006

Therapy/Procedure

18Therapeutics
01/2019 - 01/2005
10Drug Therapy (Chemotherapy)
01/2019 - 01/2004
7Lasers (Laser)
10/2010 - 01/2003
4Chemoradiotherapy
10/2016 - 02/2012
3Immunotherapy
12/2021 - 01/2010
3Adjuvant Chemotherapy
08/2016 - 04/2004
2Neoadjuvant Therapy
10/2016 - 06/2015
1Precision Medicine
01/2015
1Radiotherapy
12/2013